Contributing All the Way to the Clinic

Recently the ZoBio team made an important contribution to a drug discovery project for our client Mirati Therapeutics that we are particularly proud of and has had significant impact [1]. This work describes a program to develop inhibitors of the epigenetic target PRMT5 with the potential to …

Eurostars DiscoveRNA Project Awarded!

RNA as a potential drug target is currently gaining a lot of interest, but the right technologies are not all in place to successfully pursue them. ZoBio and its partner ETH Zurich have been awarded with a €1.2 million EUREKA Eurostars grant, to establish an automated pipeline enabling…

Remarkable NMR Achievement in Collaboration with ESSA Pharma

The androgen receptor (AR) pathway drives most metastatic, castration-resistant prostate cancers (mCRPC). Anti-androgen resistance mechanisms include AR gene amplification, C-terminal ligand-binding domain (LBD) mutations and expression of constitutively-active truncated AR splice variants lacking…